(Total Views: 837)
Posted On: 04/09/2024 12:38:56 PM
Post# of 154001
An unsung hero:
February 13, 2014:
CytoDyn Appoints Denis R. Burger, Ph.D. to Board of Directors
Provisional patent: June 23, 2015
" Methods for the therapeutic use of competitive inhibitors of the CCR5/CCL5 axis that express antagonist activity for RANTES (CCL5) for immunomodulatory treatment ...."
Jan. 20th, 2016:
CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer
“I am honored to be selected for this crucial role in the expansion of PRO 140 into immunologic indications,” said Dr. Burger. “The target for PRO 140, CCR5, plays an important role in a vast array of immune mechanisms and CytoDyn is positioned to expand the potential market for PRO 140 by pursuing these non-HIV clinical indications including transplantation, chronic inflammation, autoimmunity and cancer.”
Full patent application:
June 23, 2016
Inventor: Denis R. Burger
Assignee: Cytodyn
Date of Patent: Feb 21, 2023
______________
Self authored ( believed in ), what is now, 8 years later, a potentially stunning turn of events.
Once his steadfast belief of the MOA is solidified, the iP value of his work for Cytodyn, becomes a priceless asset for Cytodyn, to 2043.
Dr. Denis R. Burger:
An unsung hero.
https://patents.justia.com/patent/11584797
February 13, 2014:
CytoDyn Appoints Denis R. Burger, Ph.D. to Board of Directors
Provisional patent: June 23, 2015
" Methods for the therapeutic use of competitive inhibitors of the CCR5/CCL5 axis that express antagonist activity for RANTES (CCL5) for immunomodulatory treatment ...."
Jan. 20th, 2016:
CytoDyn Appoints Denis R. Burger, Ph.D., as Chief Science Officer
“I am honored to be selected for this crucial role in the expansion of PRO 140 into immunologic indications,” said Dr. Burger. “The target for PRO 140, CCR5, plays an important role in a vast array of immune mechanisms and CytoDyn is positioned to expand the potential market for PRO 140 by pursuing these non-HIV clinical indications including transplantation, chronic inflammation, autoimmunity and cancer.”
Full patent application:
June 23, 2016
Inventor: Denis R. Burger
Assignee: Cytodyn
Date of Patent: Feb 21, 2023
______________
Self authored ( believed in ), what is now, 8 years later, a potentially stunning turn of events.
Once his steadfast belief of the MOA is solidified, the iP value of his work for Cytodyn, becomes a priceless asset for Cytodyn, to 2043.
Dr. Denis R. Burger:
An unsung hero.
https://patents.justia.com/patent/11584797
(15)
(0)
